KR100577865B1 - 정신병성 질환의 치료 또는 예방을 위한 미르타자핀 및 항정신병제의 신규한 치료 조합물 - Google Patents

정신병성 질환의 치료 또는 예방을 위한 미르타자핀 및 항정신병제의 신규한 치료 조합물 Download PDF

Info

Publication number
KR100577865B1
KR100577865B1 KR1019997008745A KR19997008745A KR100577865B1 KR 100577865 B1 KR100577865 B1 KR 100577865B1 KR 1019997008745 A KR1019997008745 A KR 1019997008745A KR 19997008745 A KR19997008745 A KR 19997008745A KR 100577865 B1 KR100577865 B1 KR 100577865B1
Authority
KR
South Korea
Prior art keywords
mirtazapine
antipsychotics
treatment
haloperidol
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997008745A
Other languages
English (en)
Korean (ko)
Other versions
KR20010005677A (ko
Inventor
브로에캄프크리스토포러스루이스에듀어드
베렌드센헤르마누스헨리쿠스제라르두스
핀더로자마틴
Original Assignee
악조 노벨 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악조 노벨 엔.브이. filed Critical 악조 노벨 엔.브이.
Publication of KR20010005677A publication Critical patent/KR20010005677A/ko
Application granted granted Critical
Publication of KR100577865B1 publication Critical patent/KR100577865B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019997008745A 1997-03-27 1998-03-25 정신병성 질환의 치료 또는 예방을 위한 미르타자핀 및 항정신병제의 신규한 치료 조합물 Expired - Fee Related KR100577865B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP97200881 1997-03-27
EP97200881.7 1997-09-11
EP97202785.8 1997-09-11
EP97202785 1997-09-11
PCT/EP1998/001920 WO1998043646A1 (en) 1997-03-27 1998-03-25 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders

Publications (2)

Publication Number Publication Date
KR20010005677A KR20010005677A (ko) 2001-01-15
KR100577865B1 true KR100577865B1 (ko) 2006-05-10

Family

ID=26146283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997008745A Expired - Fee Related KR100577865B1 (ko) 1997-03-27 1998-03-25 정신병성 질환의 치료 또는 예방을 위한 미르타자핀 및 항정신병제의 신규한 치료 조합물

Country Status (24)

Country Link
EP (1) EP0969845B1 (enExample)
JP (2) JP4377456B2 (enExample)
KR (1) KR100577865B1 (enExample)
CN (1) CN1226036C (enExample)
AR (1) AR012193A1 (enExample)
AT (1) ATE318604T1 (enExample)
AU (1) AU726194B2 (enExample)
BR (1) BR9808077A (enExample)
CA (1) CA2284551C (enExample)
CZ (1) CZ298105B6 (enExample)
DE (1) DE69833645T2 (enExample)
DK (1) DK0969845T3 (enExample)
ES (1) ES2259207T3 (enExample)
HU (1) HUP0002742A3 (enExample)
ID (1) ID22283A (enExample)
IL (1) IL123716A (enExample)
NO (1) NO994673L (enExample)
NZ (1) NZ337618A (enExample)
PL (1) PL191449B1 (enExample)
PT (1) PT969845E (enExample)
RU (1) RU2222330C2 (enExample)
TR (1) TR199902334T2 (enExample)
TW (1) TW587938B (enExample)
WO (1) WO1998043646A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
US6350773B1 (en) 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
JP2004518699A (ja) 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
RU2232574C2 (ru) * 2002-04-05 2004-07-20 Новосибирский институт органической химии им. Н.Н.Ворожцова СО РАН Лекарственное средство для лечения различных форм депрессий "флуоглизин"
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
DK1541197T3 (da) * 2003-12-02 2009-06-15 Pharmaneuroboost N V Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
JP5001271B2 (ja) * 2006-06-09 2012-08-15 大日本住友製薬株式会社 新規テープ製剤
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
DE102012011839B4 (de) * 2012-06-14 2018-03-22 Norbert Müller Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen
RU2509560C1 (ru) * 2013-03-22 2014-03-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые терапевтические комбинации миртазапина для применения при болевых расстройствах

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
EP0431663B1 (en) * 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
FI111367B (fi) * 1991-02-04 2003-07-15 Aventis Pharma Inc Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet
ZA935078B (en) * 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
RU2062114C1 (ru) * 1992-09-30 1996-06-20 Московский научно-исследовательский институт психиатрии МЗ РФ Способ лечения эндогенных психозов
PT669128E (pt) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma
JPH07242669A (ja) * 1994-03-07 1995-09-19 Akikazu Ogawa 四環系とブチロフェノン誘導体を化学結合した化合物

Also Published As

Publication number Publication date
KR20010005677A (ko) 2001-01-15
HUP0002742A2 (hu) 2001-05-28
ID22283A (id) 1999-09-30
IL123716A0 (en) 1998-12-06
NZ337618A (en) 2000-06-23
AR012193A1 (es) 2000-09-27
NO994673D0 (no) 1999-09-24
PT969845E (pt) 2006-05-31
PL335890A1 (en) 2000-05-22
RU2222330C2 (ru) 2004-01-27
CZ298105B6 (cs) 2007-06-27
CA2284551C (en) 2007-06-12
CA2284551A1 (en) 1998-10-08
BR9808077A (pt) 2000-03-08
CN1251526A (zh) 2000-04-26
TW587938B (en) 2004-05-21
EP0969845A1 (en) 2000-01-12
ES2259207T3 (es) 2006-09-16
EP0969845B1 (en) 2006-03-01
TR199902334T2 (xx) 2000-01-21
DE69833645T2 (de) 2006-08-24
NO994673L (no) 1999-11-17
JP2009280596A (ja) 2009-12-03
IL123716A (en) 2001-03-19
AU7213998A (en) 1998-10-22
HUP0002742A3 (en) 2003-03-28
DK0969845T3 (da) 2006-06-19
PL191449B1 (pl) 2006-05-31
CZ343199A3 (cs) 2000-04-12
WO1998043646A1 (en) 1998-10-08
ATE318604T1 (de) 2006-03-15
DE69833645D1 (de) 2006-04-27
CN1226036C (zh) 2005-11-09
AU726194B2 (en) 2000-11-02
JP4377456B2 (ja) 2009-12-02
JP5023315B2 (ja) 2012-09-12
HK1023293A1 (en) 2000-09-08
JP2001521497A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
KR100577865B1 (ko) 정신병성 질환의 치료 또는 예방을 위한 미르타자핀 및 항정신병제의 신규한 치료 조합물
US6150353A (en) Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
KR100481254B1 (ko) 미르타자핀과하나이상의선택적인세로토닌재흡수저해제를포함하는약학조성물
US6274601B1 (en) Methods of inhibiting ulcerative mucositis
AU692490B2 (en) Methods of inhibiting dysfunctional uterine bleeding
CZ284363B6 (cs) Použití protikřečových činidel k přípravě léčiv určených k léčení Parkinsonovy choroby a Parkinsonových syndromů
EP0662325B1 (en) Inhibition of ovarian dysgenesis, delayed puberty, or sexual infantilism
US6420388B1 (en) Osanetant in the treatment of depression and depressive disorders
ES2214305T3 (es) Utilizacion de la ciamemazina en el tratamiento de la eliminacion brusca de las benzodiazepinas.
ES2275619T3 (es) Quetiapina para el tratamiento de discinesia en pacientes no psicoticos.
AU701267B2 (en) Methods of inhibiting growth hormone effects
KR20000029647A (ko) 양극성장애의치료방법
HK1023293B (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
MXPA99008791A (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
HK1009400A1 (en) Combination drug containing tramadol and a calcium channel antagonist
HK1009400B (en) Combination drug containing tramadol and a calcium channel antagonist
KR20010034817A (ko) 파록세틴을 사용한 전반적 불안장애의 치료
MXPA97004579A (en) Pharmaceutical composition comprising mirtazapine and one or more selective seroton reabsorption inhibitors
EP0898966A1 (en) Benzo(b)thiophene derivatives for inhibiting temporomandibular disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090503

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090503